Rhumbline Advisers Bio N Tech Se Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Bio N Tech Se stock. As of the latest transaction made, Rhumbline Advisers holds 120 shares of BNTX stock, worth $11,394. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120
Previous 120
-0.0%
Holding current value
$11,394
Previous $14,000
7.14%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BNTX
# of Institutions
365Shares Held
39.6MCall Options Held
3.01MPut Options Held
2.01M-
Baillie Gifford & CO8.22MShares$781 Million0.74% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.41MShares$418 Million2.03% of portfolio
-
Primecap Management CO Pasadena, CA4.3MShares$408 Million0.39% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$180 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$172 Million1.03% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $23B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...